The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II multicenter study of antroquinonol in patients with stage IV non-small cell lung cancer who have failed at least two lines of anti-cancer therapy.
 
Ching-Liang Ho
Research Funding - Golden Biotechnology
 
David S. Ettinger
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Guardant Health; Lilly
Research Funding - Golden Biotechnology (Inst)
 
Pei-Ni Chen
Employment - Golden Biotechnology
Stock and Other Ownership Interests - Golden Biotechnology
 
Howard Cheng
Employment - Golden Biotechnology
Stock and Other Ownership Interests - Golden Biotechnology
 
Wu-Che Wen
Employment - Golden Biotechnology
 
Shang-Yin Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Roche; Sanofi
 
Thierry Marie Jahan
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Lilly (Inst); Polaris (Inst); Trizell (Inst)
 
Mary J. Fidler
Honoraria - AstraZeneca
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Genentech; Genentech (I); Guardant Health; Guardant Health
Speakers' Bureau - Genentech; Merck
Research Funding - Biodesix
 
Bradley Walter Lash
No Relationships to Disclose
 
Igor I. Rybkin
Consulting or Advisory Role - AstraZeneca
 
Natalie Stanton
Research Funding - Golden Biotechnology